期刊文献+

0.03%Bimatoprost对正常无色素兔的降眼压机制研究 被引量:1

Experimental study on the mechanism of lowing intraocular pressure of bimatoprost in albino rabbits
下载PDF
导出
摘要 目的研究前列腺素类似物的新成员—Bimatoprost的降眼压机制。方法将正常无色素兔双眼滴入0.03%Bimatoprost,按用药时间分为5组,应用酶谱分析法,检测滴用Bimatoprost不同时间后兔眼睫状肌匀浆上清液及房水中基质金属蛋白酶(MMPs)的变化并进行半定量分析;制备不同用药时间的兔眼球病理切片及超薄切片,观察药物对兔眼各层组织及睫状肌细胞的影响。结果随用药时间的延长,MMP-1/2在兔眼睫状肌匀浆上清液中的活性增加,而在房水中则无明显变化。Bimatoprost可引起睫状肌松弛,睫状肌间隙增宽。睫状肌细胞间连接逐渐消失,细胞间隙增大,细胞外基质减少。结论滴用0.03%Bimatoprost后,兔眼睫状肌细胞中的MMPs合成增加,活性增强,睫状肌细胞外基质减少,这些变化可降低葡萄膜巩膜通道的阻力,增加房水外流,构成了Bimatoprost降眼压机制的重要组成部分。 Objective Our previous study showed Bimatoprost has a obvious effect suppressing intraocular pressure (IOP) ,but its active mechanism is worth studing. Our study was to evaluate the mechanism of lowing IOP of 0. 03% Bimatoprost in albino rabbits. Methods Fifty normal albino rabbits were divided into 5 groups randomly based on the duration of medication. 25 μL of 0. 03% Bimatoprost eye drops was administrated topically once per day for 3,7,14 and 21 days, respectively in experimental groups, and the normal saline solution was given at a same way in the control group. The activity of matrix metalloproteinases (MMPs) in rabbit ciliary smooth muscle cells and aqueous humour was assayed after usage of drug using gelatin SDS-PAGE zymography. Bands intensity( the activity of MMPs) was measured by UVI. The morphology of eye wall and anterior chamber angle after administration of drug was observed by SMA and HE staining. The morphological alterations of ciliary muscle cells,extracellular space and MMPs were examined under the transmission electron microscope. Results After treated with 0. 03% Bimatoprost,the activity of MMP-1/2 in ciliary muscle increased by 23.43% ,64. 69% ,89.30% and 119.66% in 3,7,14 and 21 days respectively after administration of drug, but that in aqueous humor was unchanged. The ciliary smooth muscle was relaxed and intercellular space of ciliary smooth muscle cells increased after being treated with 0. 03% Bimatoprost. The desmosome among ciliary muscle cells decreased in number and got loose and irregular, and the collagen in extracellular matrix was decreased. Conclusion Application of 0. 03% Bimatoprost decrease the resistance of the uveoscleral outflow pathway and facilitate the aqueous fluid outflow by enhancing MMPs activity and reducing ECM components around ciliary muscle cells.
作者 李欣 赵家良
出处 《眼科研究》 CSCD 北大核心 2007年第12期919-922,共4页 Chinese Ophthalmic Research
关键词 青光眼 前列腺素类似物 基质金属蛋白酶 0.03%Bimatoprost glaucoma prostaglandins matrix metalloproteinases O. 03% Bimatoprost
  • 相关文献

参考文献12

  • 1Brubaker RF,Schoff EO,Nau CB,et al. Effects of AGN 192024,a new ocular hypotensive agent,on aqueous dynamics [ J]. Am J Ophthalmol, 2001,131: 19-24.
  • 2李欣,赵家良.0.03%Bimatoprost对正常无色素兔的降眼压作用及安全性研究[J].眼科研究,2007,25(4):288-291. 被引量:2
  • 3Cantor LB. Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management [ J ]. Exp Opin Invest Drugs, 2001,10: 721-731.
  • 4Eugenia B, Jean MF. Matrix metalloproteinase family [ J ]. Cell Biol Intern, 1995,19:239-242.
  • 5Nilsson SF. The uveoscleral outflow routes[ J]. Eye, 1997,11 : 149-154.
  • 6Lutjen DE, Tamm E. Morphological study of the anterior segment of eynomolgus monkey eyes following treatment with prostaglandin F2α[ J]. Exp Eye Res, 1988,47: 761-769.
  • 7Sardar YK,Zhi Ye, Ata AAL. Prostaglandin F2αand its analogs induce release of endogenous prostaglandins in iris and ciliary muscles isolated from cat and other mammalian species [ J ]. Exp Eye Res, 1996,63 : 305-310.
  • 8Ferreira SH, Vane JR. Prostalandins: their disappearance from and release into the circulation[J]. Nature, 1967,216: 868-873.
  • 9Nilsson SF,Samuelsson M, Bill A,et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2α1-isopropylester in the cynomolgus monkey [ J ]. Exp Eye Res, 1989,48: 707-716.
  • 10Weinreb RN, Kashiwagi K, Kashiwagi F, et al. Prostaglandins increase metalloproteinase activity in medium of human ciliary smooth muscle cells in vitro[ J]. Invest Ophthalmol Vis Sci,1997,38: 2772-2780.

二级参考文献11

  • 1Thomas WH,Camras CB.Prostaglandin analogs in the treatment of glaucoma[J].Semi Ophthalmol,1999,14:114-123
  • 2Brubaker RF,Schoff EO,Nau CB,et al.Effects of AGN 192024,a new ocular hypotensive agent,on aqueous dynamics[J].Am J Ophthalmol,2001,131:19 -24
  • 3Cantor LB.Bimatoprost:a member of a new class of agents,the prostamides,for glaucoma management[J].Exp Opin Invest Drugs,2001,10:721 -731
  • 4Sherwood M,Brandt J.Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure[J].Surv Ophthalmol,2001,45 (4):S361-368
  • 5Brandt JD,VanDenburgh AH,Chen K,et al.Comparison of once or twicedaily bimatoprost with twice-daily timolol in patients with elevated IOP[J].Ophthalmology,2001,108:1023-1029
  • 6Camras CB.Bimatoprost vs.timolol[J].Ophthalmology,2002,109:627-629
  • 7Dubiner H,Cooke D,Dirks M,et al.Efficacy and safety of bimatoprost in patients with elevated intraocular pressure:a 30-day comparison with latanoprost[J].Surv Ophthalmol,2001,45:S353-360
  • 8Cantor LB,Hoop J,Morgan L,et al.Intraocular pressure-lowering efficacy of bimatoprost 0.03% and travoprost 0.004% in patients with glaucoma or ocular hypertension[J].Br J ophthalmol,2006,90(11):1370-1373
  • 9Guenoun JM,Baudouin C,In vitro study of inflammatory potential and toxicity profile of latanoprost,travoprost,and bimatoprost in conjunctivaderived epithelial cells[J].Invest Ophthalmol Vis Sci,2005,46 (7):2444-2450
  • 10Gelatt KN,Mackay EO.Effect of different dose schedules of bimatoprost on intraocular pressure and pupil size in the glaucomatous beagle[J].J Ocul Pharmacol Ther,2002,18 (6):525-534

共引文献1

同被引文献12

  • 1李欣,赵家良.0.03%Bimatoprost对正常无色素兔的降眼压作用及安全性研究[J].眼科研究,2007,25(4):288-291. 被引量:2
  • 2Wu LL,Huang P, Gao YX, et al. A 12-week, double-masked, parallel- group study of the safety and efficacy of travoprost O. 004% compared with pilocarpine 1% in Chinese patients with primary angle-closure and primary angle-closure glaucoma[J]. J Glaucoma,2011,20:388-391.
  • 3Toris CB, Camras CB, Yablonski ME, et al. Effects of exogenous prostaglandins on aqueous humor dynatics and blood-aqueous barrierfunction[J]. Surv Ophthalmol, 1997,41 ( suppl 2 ) :S69-S75.
  • 4Nilsson SFE,Samublsson M, Bill A,et al. Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2 alpha-l-isopropylester in the cynomolgus monkey [ J ]. Exp Eye Res, 1989,48 : 707-716.
  • 5Yousufzai SY, Zheng P, Abdel-Latif AA. Musearinic stimulation of arachidonic acid release and prostaglandin synthesis in bovine ciliary muscle: prostaglandins induce cyclic AMP formation and muscle relaxation[J]. Exp Eye Res, 1994,58 : 513-522.
  • 6Toor A, Chanis RA, Polik off LA, et al. Additivity of pilocarpine to bimatoprost in ocular hypertension and early glaucoma[ J ]. J Glaucoma, 2005,14 : 243 -248.
  • 7Kent AR, Vroman DT,Thomas TJ, et al. Interaction of pilocarpine with latanoprost in patients with glaucoma and ocular hypertension[J]. J Glaucoma, 1999,8 : 257-262.
  • 8Diestelhorst M. The additive intraocular pressure-lowering effect of latanoprost 0. 005% daily once and pilocarpine 2% t. i. d. in patients with open-angle glaucoma or ocular hypertension, a 6-month,randomized, muhicenter study. German Latanoprost Study Group[ J]. Graefe' s Arch Clin Exp Ophthalmol,2000,238 : 433-439.
  • 9Sarchahi AA,Abbasi N, Gholipour MA. Effects of an unfixed combination of latanoprost and pilocarpine on the intraocular pressure and pupil size of normal dogs[J]. Vet Ophthalmo1,2012,15 ( Suppl 1 ) :S64-S70.
  • 10Hoyng PF, Rulo A, Greve E, et al. The additive intraocular pressure- lowering effect of latanoprost in combined therapy with other ocular hypotensive agents [ J ]. Surv Ophthalmol, 1997,41( Suppl 2 ) :S93-S98.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部